The consolidated performance forecast and dividend forecast for Q1–Q2 fiscal 2021 (April 1, 2021 – September 30, 2021) announced on May 13, 2021, have been revised as shown below based on recent performance trends.
1. Revision of consolidated forecast for Q1–Q2 fiscal 2021
Previous forecast
(¥ million)
(¥ million)
(¥ million)
owners of the parent
(¥ million)
(¥)
Revised forecast
(¥ million)
(¥ million)
(¥ million)
owners of the parent
(¥ million)
(¥)
Increase (decrease)
(¥ million)
(¥ million)
(¥ million)
owners of the parent
(¥ million)
(¥)
Percent change
(¥ million)
(¥ million)
(¥ million)
owners of the parent
(¥ million)
(¥)
cf. Q1–Q2 fiscal 2020
(¥ million)
(¥ million)
(¥ million)
owners of the parent
(¥ million)
(¥)
2. Reason for revision of performance forecast
Net sales, operating income, and ordinary income are now expected to exceed the previous forecast with firm performance in each sector. Net income attributable to owners of the parent is now expected to fall short of the previous forecast due to postponement of a planned income tax reduction of approximately ¥24.0 billion in connection with reconfiguration of organizations related to Veloxis Pharmaceuticals, Inc., in the Health Care sector.
The full-year forecast for fiscal 2021 has not been revised.
3. Revision of dividend forecast for fiscal 2021
Cash dividends per share (¥)
4. Reason for revision of dividend forecast
The company's basic policy is to balance investments for growth and shareholder returns by maintaining an appropriate internal reserve while aiming for stable dividends and dividend increases through continuous expansion of earnings.
The interim dividend and year-end dividend for fiscal 2021 are now each forecasted to be ¥17 per share based on a resolution of the Board of Directors dated August 6, 2021, in consideration of the above stated policy.
In accordance with Asahi Kasei's Articles of Incorporation, interim dividends are determined by resolution of the Board of Directors.